Multimodal therapy in malignant pleural mesothelioma (MPM) M. H. Serke, N. Schoenfeld, D. Kaiser, A. Fisseler-Eckhoff, R. Loddenkemper (Berlin, Germany; Berlin)
Source: Annual Congress 2002 - Thoracic oncology: clinical management
Session: Thoracic oncology: clinical management Session type: Poster DiscussionNumber: 1194
Disease area: Thoracic oncologyAbstract The clinical courses of 260 patients (pat.) ot our hospital with malignant pleural mesothelioma (MPM) were evaluated. Patients and therapy: Between 1985 and 2001 we treated 260 pat. with MPM. 214 (82%) were male, 46 (18%) were of female gender. The median age was 62 years (range 31-88). Mostly the diagnosis was made by medical thorascopy, confirmed by palliative pleurectomy or autopsy. In good performance pat. our strategy was to perform surgery (mostly partial pleurectomy) followed by 3-6 cycles of cisplatinum-based chemotherapy (DDP/EPI or DDP/Gem). Results: Histological types: epitheloid 61%, biphasic 32%, sarcomatoid 7%. The median survival (Kaplan-Meier) of all patients was 364 days, 1-year-survival was 50% and 2-years-survival 18%. 127 pat. had chemotherapy (48%), 75 of them after surgery. 112 pat. underwent surgery, mostly palliative pleurectomy (43%), 37 had no chemotherapy. Survival was better in the epitheloid group compared to the sarcomatoid group and better in the ECOG 0-1 pat. compared to ECOG 2-3 pat. Conclusion: Multimodal therapy of MPM is feasible. Median survival is comparable to non-small-cell lung cancer. The influence of chemotherapy and surgery must be evaluated in randomised trials. Supported by Verein zur Förderund der Pneumonologie und Thoraxchirurgie.Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. H. Serke, N. Schoenfeld, D. Kaiser, A. Fisseler-Eckhoff, R. Loddenkemper (Berlin, Germany; Berlin). Multimodal therapy in malignant pleural mesothelioma (MPM). Eur Respir J 2002; 20: Suppl. 38, 1194
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: